Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAcute LeukemiasAggressive LymphomasCellular TherapyIndolent LymphomasDiseaseAcute Lymphoblastic LeukaemiaCAR T-Cell TherapyChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaMantle Cell LymphomaNHL, B-Cell Type, Burkitt's LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentSubgroupICD10C82.-C82.7C82.9C83.1C83.3C83.7C91.0-C91.1-MeSHLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellPrecursor B-Cell Lymphoblastic Leukemia-LymphomaSequenceIXAZ4/RITU1400/DEXA20, Waldenström (PID2025) -|- (PID2026) -|- (PID2027) -|- (PID310)OFAR (OXAL25/FLUD30/CYTA1000/RITU375), CLL (Richter Syndrome), C1 (PID828) -|- C2+ (PID829)ChemotherapyChemo-substanceCyclophosphamideCytarabineFludarabineOxaliplatinRituximabChemo-substanceCyclophosphamideCytarabineFludarabineOxaliplatinRituximabChemo-substanceCyclophosphamideCytarabineFludarabineOxaliplatinRituximabChemo-substanceCyclophosphamideCytarabineFludarabineOxaliplatinRituximabNo. Substances124 RadiotherapySupportive therapySupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenGranisetronParacetamolPegfilgrastimPrednisoloneNo. Substances39Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationRelapse therapyseveral possibleTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlDiarrheaEmetogenicity (MASCC/ESMO)Febrile NeutropeniaHemorrhageHypertensionLymphopeniaNeutropeniaThrombocytopenia below 50 000/µl only studiesPublicationAuthorDavies ALiu E Tsimberidou ADiseaseB-NHL, rezidiviert oder therapierefraktär, CD19- positiv, Lymphodepletion vor CAR T-Zell TherapieFludarabin-refraktäre CLL oder Transormation zum Richter Syndrom, ECOG 0-2OriginCancer Research UK Centre, University of Southampton, UK, SABRINA StudieDepartments of Leukemia and Experimental Therapeutics, The University of Texas, Anderson Cancer Center Departments of Leukemia and Experimental Therapeutics, The University of Texas, Anderson Cancer Center HoustonUniversity of Texas M.D. Anderson Cancer Center, HoustonProtocols in Revision 4 protocols foundProtocols under revision.Fludarabine 30 / Cyclophosphamide 300, B-non-Hodgkin Lymphoma, Lymphodepletion (PID2471 V2.0)OFAR - Oxaliplatin 25 / Fludarabine 30 / Cytarabine 1000 / Rituximab 375, Chronic Lymphocytic Leukemia, Richter Syndrome, cycle 1 (PID828 V1.0)OFAR - Oxaliplatin 25 / Fludarabine 30 / Cytarabine 1000 / Rituximab 375, Chronic Lymphocytic Leukemia, Richter Syndrome, cycle 2+ (PID829 V1.0)Rituximab 1400, single dose subcutaneous (PID310 V2.0)
